H5N1 whole virus influenza vaccine (Daronrix) - GlaxoSmithKline

Drug Profile

H5N1 whole virus influenza vaccine (Daronrix) - GlaxoSmithKline

Alternative Names: Daronrix; Pre-pandemic mock-up vaccine (Daronrix) - GlaxoSmithKline

Latest Information Update: 24 Mar 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ID Biomedical Corporation
  • Developer GlaxoSmithKline
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Influenza A virus H5N1 subtype

Most Recent Events

  • 21 Mar 2007 Registered for Influenza-A virus H5N1 subtype in European Union (IM)
  • 31 Dec 2005 Preregistration for Influenza-A virus H5N1 subtype in European Union (IM)
  • 24 Jan 2005 Preclinical trials in Influenza-A virus H5N1 subtype in Canada (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top